SPOC MIRACIP: Management of immunorelated complication of cancer immunotherapy
… adverse events (irAEs). These irAEs are unique and are different to those of traditional cancer therapies, and typically have delayed onset … with an unexpected clinical sign, the physician must differentiate rapidly between an irAE, cancer progression, … adverse events (irAEs). These irAEs are unique and are different to those of traditional cancer therapies, and …
Published on: